活性维生素D_3治疗慢性肾脏病Ⅰ～Ⅲ的临床观察

245.

论 著

23

[5] Qureshi AI,Sung GY,Razumovsky AY,et al.Early identification

of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage[J].Crit Care Med,2000,28(4):984–990.[6] Hijdra A,van Gijn J,Nagelkerke NJ,et al.Prediction of delayed

cerebral ischemia,rebleeding,and outcome after aneurysmal subarachnoid hemorrhage[J].Stroke,1988,19(10):1250 –1256.[7] Chan MT,Boel R,Ng SC,et a1.Magnesium sulfate for brain

protection during temporary cerebral artery occlusion[J].Acta Neureehir Suppl,2005,95:107-111.

[8] Muir KW,Lees KR,Ford I,et a1.Intravenous Magnesium Efficacy

in Stroke(IMAGES)Study Investigators.Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial):randomised controlled trial[J].Lancet,2004,363(9407):439-445.[9] 罗伟良,邱淑莲,马卫东.硫酸镁防治蛛网膜下腔出血后迟发性

脑血管痉挛的疗效观察[J].临床神经病学杂志,1996,9(4):244-

[10] Ram Z, Sadeh M,Shacked I,et al.Magnesium sulfate reverses

experimental delayed cerebral vasospasm after subarachnoid hemorrhage in rats[J].Stroke,1991,22(7):922-927.

[11] Walter M,Van den Bergh,on behalf of the MASH Study Group.

Magnesium sulfate in aneurismal subarachnoid hemorrhage: a randomized controlled trial[J].Stroke,2005,36(5):1011-1015.[12] Muir KW,Lees KR.Dose optimization of intravenous magnesium

sulfate after acute stroke[J].Stroke,1998,29(5):918-923.

[13] 贺建华,马毳,张茁,等.静脉注射硫酸镁治疗急性脑卒中的剂量

选择[J].脑与神经疾病杂志,2001,9(6):345-347.

[14] 贾卓鹏.镁在高血压脑出血急性期应用的临床研究[J].实用医技

杂志,2006,13(24):4389-4390.

[15] 武媫,章柏松.ET和NO在脑出血中变化以及硫酸镁的干预作

用[J].中国血液流变学杂志,2004,4(1):32-36.

活性维生素D3治疗慢性肾脏病（Ⅰ～Ⅲ）的临床观察

田秋菊

（菏泽市立医院肾内科，山东 菏泽 274031）

【摘要】目的 观察活性维生素D3治疗慢性肾脏病（chronic kidney disease，CKD）（Ⅰ~Ⅲ期）的疗效及安全性，旨在探讨治疗CKD（Ⅰ~Ⅲ期）安全、有效的新方法。方法 将符合CKD（Ⅰ~Ⅲ期）的100例住院患者随机分为活性维生素D3治疗组（n=50）和对照组（n=50）根据不同的病因，尿蛋白定量、肾功能情况、病理类型及血压等情况给予相应的常规治疗。治疗组在对照组的基础上给予活性维生素D3（骨化三醇）1.0mg/d口服，观察12周，主要观察尿蛋白量下降程度、肾功能变化情况及血清钙、磷水平。结果 治疗组尿蛋白显著下降[（3.99±1.25）g vs（1.05±0.33）g/24h，P＜0.01]，血尿素氧（BUN）、血肌酐（Scr）亦明显下降。[（6.8±3.1）mmol/L vs （4.2±1.1）μmol/L，

P＜0.05]、[（128.5±60.5）μmol/L vs （98±40.1） μmol/L，P＜0.05]。对照组尿蛋白亦明显下降[（3.73±1.32g） vs （2.11±0.98）

g/24h，P＜0.05]，BUN，Scr无明显变化，[（7.0±2.8）mmol/L vs （6.8±1.4）mmol/L，P＞0.05]，[（130.1±61.8） μmol/L VS（129±50.3） μmol/L，P＞0.05]，两组血清钙均略有升高，但无统计学差异。结论 活性维生素D3能明显减少CKD（Ⅰ~Ⅲ期）患者尿蛋白，延缓肾功能进展，疗效优于对照组，且无明显副作用，是治疗CKD（Ⅰ~Ⅲ期）安全，有效的药物。【关键词】慢性肾脏病；活性维生素D3

中图分类号：R692 文献标识码：B 文章编号：1671-8194（2012）04-0023-02

Ｔｈｅ　Ｃｌｉｎｉｃａｌ　Ｏｂｓｅｒｖａｔｉｏｎ　ｏｆ　Ａｃｔｉｖｅ　Ｖｉｔａｍｉｎ　Ｄ３　Ｔｒｅａｔｍｅｎｔ　ｏｆ　Ｃｈｒｏｎｉｃ　Ｋｉｄｎｅｙ　Ｄｉｓｅａｓｅ　（Ⅰ￣Ⅲ）　

TIAN Qiu-ju

(Department of Nephrology, Heze Municipal Hospital, Heze 274031, China)

[Abstract] Objective To Observe the efficacy and safety of the active vitamin D3 to treat chronic kidney disease (CKD) (I-III period). To investigate the safe and effective new methods to treat CKD (I-III period). Methods 100 hospitalized patients who were consistent with CKD (I-III period) were randomly divided into the active vitamin D3 treatment group (n = 50) and the control group (n = 50). Depending on the cause of disease, urine protein, renal function, pathology and blood pressure, etc. the control group were given the corresponding conventional treatment. On the basis of treatment in the control group, the treatment group were given active vitamin D3 (calcitriol) 1.0μg / d orally. Having Observed for 12 weeks. Observed decline in the major urinary protein level, changes in renal function and serum calcium and phosphorus levels. Results The urinary protein in the treatment group decreased significantly [(3.99 ± 1.25) vs (1.05 ± 0.33) g/24h, P＜0.01], blood urea nitrogen (BUN), serum creatinine (Scr) also decreased significantly. [(6.8 ± 3.1) mmol / L vs (4.2 ± 1.1) mmol/L,

P＜0.05], [(128.5 ± 60.5) μmol/L vs (98 ± 40.1) μmol/L, P＜0.05]. The urinary protein of the control group also decreased. [(3.73 ± 1.32) g vs (2.11 ± 0.98)

g/24h, P＜0.05]. BUN and Scr had no significant changes. [(7.0 ± 2.8) mmol/L vs (6.8 ± 1.4) mmol/L, P＞0.05], [(130.1 ± 61.8) μmol / L vs (129 ± 50.3) μmol/L, P＞0.05]. The serum calcium in two groups was slightly higher, but not significantly. Conclusion The active vitamin D3 can significantly reduce the CKD (I-III stage) in patients with urinary protein, slow down the progress of renal function, is more effective than the control group with no significant side effects. It is the safe and effective drugs to treat CKD (I-III stage).[Key words] Chronic …… 此处隐藏：5329字，全部文档内容请下载后查看。喜欢就下载吧 ……